수술중 신경 모니터링 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 정보원별, 유형별, 지역별, 부문별 예측(2025-2030년)

Intraoperative Neuromonitoring Market Growth & Trends:

The global intraoperative neuromonitoring market size is expected to reach USD 4.66 billion in 2030 and is anticipated to grow at a CAGR of 5.97% over the forecast period. This growth can be attributed to technological advancements, increasing awareness regarding the safety of the devices, and the growing geriatric population. The COVID-19 outbreak is expected to have a dual impact on the market. In March 2020, the American College of Surgeons (ACS) published a proposal to reduce, postpone, or cancel elective surgeries as COVID-19 cases grew quickly in the U.S., which is expected to hamper growth.

Moreover, according to a research study published in Elsevier journal (International Hemorrhagic Stroke Association; Jan 2021), up to 36% of hospitalized COVID-19 patients might exhibit neurological symptoms, and there were several cases related to ischemic & hemorrhagic infarction. In addition, another recent research study published in Neurology Online Journal in June 2021 proposed that the COVID-19 virus might be responsible for patients acquiring novel neurological diseases. Owing to the growth of new diseases, there is a higher risk of in-hospital mortality and a low discharge rate. These characteristics are expected to result in lucrative growth over the forecast period.

Furthermore, the market is expected to witness growth due to the increasing number & affordability of neurosurgeries and the growing emphasis on patient safety in surgeries. Hospitals are adopting Intraoperative Neuromonitoring (IONM) in a wide spectrum of surgeries, as it reduces the number of revision surgeries and results in fewer postoperative complications & cases of permanent impairment.

Intraoperative Neuromonitoring Market Report Highlights:

• By type, the insourced segment accounted for the largest share of 52.72% in 2024. This can be attributed to growing awareness among physicians as well as patients about the benefits of IONM, which results in the hospitals utilizing IONM during complex procedures. This is a key reason for the dominance of insourced IONM in the market
• By region, North America accounted for the largest share of 49.35% in 2024. Favorable reimbursement scenarios along with technological advancements can be attributed to this dominance
• The intraoperative neuromonitoring market in Europe is anticipated to grow fastest with a CAGR of 6.38% during the forecast period

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Source
  • 1.2.3. Type
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Intraoperative Neuromonitoring Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing demand for IONM in hospitals
    • 3.2.1.2. Technological advancements in intraoperative neuromonitoring systems
    • 3.2.1.3. Increasing prevalence of neurovascular disorders
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Complex regulatory framework
    • 3.2.2.2. Surgery-associated risk
• 3.3. Intraoperative Neuromonitoring Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Intraoperative Neuromonitoring Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)

• 4.1. Intraoperative Neuromonitoring Market: Product Outlook and Key Takeaways
• 4.2. Intraoperative Neuromonitoring Market: Product Movement Analysis
• 4.3. Intraoperative Neuromonitoring Market Estimates & Forecast, by Product (USD Million)
• 4.4. Systems
  • 4.4.1. Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Disposables
  • 4.5.1.1. Disposables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. EMG Tubes And Electrodes
    • 4.5.2.1. EMG Tubes And Electrodes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Sticker Electrode
    • 4.5.3.1. Sticker Electrode Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Stimulating Probes
    • 4.5.4.1. Stimulating Probes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Intraoperative Neuromonitoring Market - Segment Analysis, by Source, 2018 - 2030 (USD Million)

• 5.1. Intraoperative Neuromonitoring Market: Source Outlook and Key Takeaways
• 5.2. Intraoperative Neuromonitoring Market: Source Movement Analysis
• 5.3. Intraoperative Neuromonitoring Market Estimates & Forecast, by Source (USD Million)
• 5.4. Insourced
  • 5.4.1. Insourced Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Outsourced
  • 5.5.1. Outsourced Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Intraoperative Neuromonitoring Market - Segment Analysis, by Type, 2018 - 2030 (USD Million)

• 6.1. Intraoperative Neuromonitoring Market: Type Outlook and Key Takeaways
• 6.2. Intraoperative Neuromonitoring Market: Type Movement Analysis
• 6.3. Intraoperative Neuromonitoring Market Estimates & Forecast, by Type (USD Million)
• 6.4. Intermittent Monitoring
  • 6.4.1. Intermittent Monitoring Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Continuous Monitoring
  • 6.5.1. Continuous Monitoring Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Intraoperative Neuromonitoring Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Recent Developments & Impact Analysis by Key Market Participants
• 8.3. Company Market Share Analysis, 2024
• 8.4. Key Company Profiles
  • 8.4.1. Natus Medical Incorporated
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Medtronic
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Accurate Monitoring
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Neuromonitoring Technologies
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. NuVasive, Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. SpecialtyCare, LLC
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Neurosoft
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Ambu A/S
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Brainlab (Dr. Langer Medical GmbH)
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Welcony (Neurosign UK Ltd.)
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives